Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.

iScience

Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE, Carnahan RH.
PMID: 34901783
iScience. 2021 Dec 08;103602. doi: 10.1016/j.isci.2021.103602. Epub 2021 Dec 08.

The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for...

Cite
Gilchuk P, Thomsen I, Yoder S, et al. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience. 2021;103602doi: 10.1016/j.isci.2021.103602.
Gilchuk, P., Thomsen, I., Yoder, S., Brady, E., Chappell, J. D., Stevens, L. J., Denison, M. R., Sutton, R. E., Chen, R. E., VanBlargan, L. A., Suryadevara, N., Zost, S. J., Schmitz, J., Pulley, J. M., Diamond, M. S., Rhoads, J. P., Bernard, G. R., Self, W. H., Rice, T. W., Wheeler, A. P., Crowe, J. E., & Carnahan, R. H. (2021). Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience, 103602. https://doi.org/10.1016/j.isci.2021.103602
Gilchuk, Pavlo, et al. "Standardized two-step testing of antibody activity in COVID-19 convalescent plasma." iScience vol. (2021): 103602. doi: https://doi.org/10.1016/j.isci.2021.103602
Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE, Carnahan RH. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. iScience. 2021 Dec 08;103602. doi: 10.1016/j.isci.2021.103602. Epub 2021 Dec 08. PMID: 34901783; PMCID: PMC8653399.
Copy Download .nbib Format: NLM
Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos.

Emerging infectious diseases

Black AP, Khounvisith V, Xaydalasouk K, Sayasinh K, Sausy A, Muller CP, Hübschen JM.
PMID: 34932463
Emerg Infect Dis. 2022 Jan;28(1):256-259. doi: 10.3201/eid2801.211307.

During 2017-2019, a total of 88/753 (11.7%) of patients 5-90 years of age in hospitals in Saravan Province, Laos, were seropositive for hepatitis C virus antibodies. Viral RNA was found in 44 samples. Sequencing showed high diversity within genotype...

Cite
Black AP, Khounvisith V, Xaydalasouk K, et al. Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerg Infect Dis. 2022;28(1):256-259doi: 10.3201/eid2801.211307.
Black, A. P., Khounvisith, V., Xaydalasouk, K., Sayasinh, K., Sausy, A., Muller, C. P., & Hübschen, J. M. (2022). Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerging infectious diseases, 28(1), 256-259. https://doi.org/10.3201/eid2801.211307
Black, Antony P, et al. "Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos." Emerging infectious diseases vol. 28,1 (2022): 256-259. doi: https://doi.org/10.3201/eid2801.211307
Black AP, Khounvisith V, Xaydalasouk K, Sayasinh K, Sausy A, Muller CP, Hübschen JM. Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerg Infect Dis. 2022 Jan;28(1):256-259. doi: 10.3201/eid2801.211307. PMID: 34932463.
Copy Download .nbib Format: NLM
Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR.
PMID: 34971849
J Clin Virol. 2021 Dec 21;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21.

Over 90% of the COVID-19 patients manifest mild/moderate symptoms or are asymptomatic. Although comorbidities and dysregulation of immune response have been implicated in severe COVID-19, the host factors that associate with asymptomatic or mild infections have not been characterized....

Cite
Anantharaj A, Gujjar S, Verma N, et al. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2021;146:105060doi: 10.1016/j.jcv.2021.105060.
Anantharaj, A., Gujjar, S., Verma, N., Khan, N. A., Shaman, H., Sharanabasava, P., Das, A., Pandey, R., Pandey, A. K., & Medigeshi, G. R. (2021). Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 146105060. https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj, Anbalagan, et al. "Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses." Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology vol. 146 (2021): 105060. doi: https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2021 Dec 21;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21. PMID: 34971849; PMCID: PMC8687718.
Copy Download .nbib Format: NLM
Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting.

Diagnostics (Basel, Switzerland)

Lownik JC, Farrar JS, Way GW, McKay A, Roychoudhury P, Greninger AL, Martin RK.
PMID: 34679489
Diagnostics (Basel). 2021 Sep 28;11(10). doi: 10.3390/diagnostics11101788.

SARS-CoV-2, the virus responsible for COVID-19, emerged in late 2019 and has since spread throughout the world, infecting over 200 million people. The fast spread of SARS-CoV-2 showcased the need for rapid and sensitive testing methodologies to help track...

Cite
Lownik JC, Farrar JS, Way GW, et al. Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. Diagnostics (Basel). 2021;11(10)doi: 10.3390/diagnostics11101788.
Lownik, J. C., Farrar, J. S., Way, G. W., McKay, A., Roychoudhury, P., Greninger, A. L., & Martin, R. K. (2021). Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. Diagnostics (Basel, Switzerland), 11(10), . https://doi.org/10.3390/diagnostics11101788
Lownik, Joseph C, et al. "Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting." Diagnostics (Basel, Switzerland) vol. 11,10 (2021). doi: https://doi.org/10.3390/diagnostics11101788
Lownik JC, Farrar JS, Way GW, McKay A, Roychoudhury P, Greninger AL, Martin RK. Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. Diagnostics (Basel). 2021 Sep 28;11(10). doi: 10.3390/diagnostics11101788. PMID: 34679489; PMCID: PMC8534650.
Copy Download .nbib Format: NLM
Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR.
PMID: 34971849
J Clin Virol. 2021 Dec 21;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21.

Over 90% of the COVID-19 patients manifest mild/moderate symptoms or are asymptomatic. Although comorbidities and dysregulation of immune response have been implicated in severe COVID-19, the host factors that associate with asymptomatic or mild infections have not been characterized....

Cite
Anantharaj A, Gujjar S, Verma N, et al. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2021;146:105060doi: 10.1016/j.jcv.2021.105060.
Anantharaj, A., Gujjar, S., Verma, N., Khan, N. A., Shaman, H., Sharanabasava, P., Das, A., Pandey, R., Pandey, A. K., & Medigeshi, G. R. (2021). Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 146105060. https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj, Anbalagan, et al. "Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses." Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology vol. 146 (2021): 105060. doi: https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2021 Dec 21;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21. PMID: 34971849; PMCID: PMC8687718.
Copy Download .nbib Format: NLM
Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies.

Journal of inflammation research

Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, Öllinger R, Dziodzio T, Maier P, Plewe JM, Horst D, Sauer IM, Pratschke J, Lachmann N, Eurich D.
PMID: 34188517
J Inflamm Res. 2021 Jun 23;14:2697-2712. doi: 10.2147/JIR.S307778. eCollection 2021.

BACKGROUND: Donor-specific antibodies (DSA) against donor human leukocyte antigen after liver transplantation, which are associated with histological changes, have been widely studied with respect to their sustained impact on transplant function. However, their long-term impact after liver transplantation remains...

Cite
Gül-Klein S, Hegermann H, Röhle R, et al. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. J Inflamm Res. 2021;14:2697-2712doi: 10.2147/JIR.S307778.
Gül-Klein, S., Hegermann, H., Röhle, R., Schmelzle, M., Tacke, F., Schöning, W., Öllinger, R., Dziodzio, T., Maier, P., Plewe, J. M., Horst, D., Sauer, I. M., Pratschke, J., Lachmann, N., & Eurich, D. (2021). Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. Journal of inflammation research, 142697-2712. https://doi.org/10.2147/JIR.S307778
Gül-Klein, Safak, et al. "Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies." Journal of inflammation research vol. 14 (2021): 2697-2712. doi: https://doi.org/10.2147/JIR.S307778
Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, Öllinger R, Dziodzio T, Maier P, Plewe JM, Horst D, Sauer IM, Pratschke J, Lachmann N, Eurich D. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. J Inflamm Res. 2021 Jun 23;14:2697-2712. doi: 10.2147/JIR.S307778. eCollection 2021. PMID: 34188517; PMCID: PMC8236257.
Copy Download .nbib Format: NLM
Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos.

Emerging infectious diseases

Black AP, Khounvisith V, Xaydalasouk K, Sayasinh K, Sausy A, Muller CP, Hübschen JM.
PMID: 34932463
Emerg Infect Dis. 2022 Jan;28(1):256-259. doi: 10.3201/eid2801.211307.

During 2017-2019, a total of 88/753 (11.7%) of patients 5-90 years of age in hospitals in Saravan Province, Laos, were seropositive for hepatitis C virus antibodies. Viral RNA was found in 44 samples. Sequencing showed high diversity within genotype...

Cite
Black AP, Khounvisith V, Xaydalasouk K, et al. Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerg Infect Dis. 2022;28(1):256-259doi: 10.3201/eid2801.211307.
Black, A. P., Khounvisith, V., Xaydalasouk, K., Sayasinh, K., Sausy, A., Muller, C. P., & Hübschen, J. M. (2022). Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerging infectious diseases, 28(1), 256-259. https://doi.org/10.3201/eid2801.211307
Black, Antony P, et al. "Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos." Emerging infectious diseases vol. 28,1 (2022): 256-259. doi: https://doi.org/10.3201/eid2801.211307
Black AP, Khounvisith V, Xaydalasouk K, Sayasinh K, Sausy A, Muller CP, Hübschen JM. Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. Emerg Infect Dis. 2022 Jan;28(1):256-259. doi: 10.3201/eid2801.211307. PMID: 34932463; PMCID: PMC8714196.
Copy Download .nbib Format: NLM
Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.

Intervirology

Yelemkoure ET, Yonli AT, Sombie HK, Tao I, Zouré AA, Ouattara AK, Sorgho AP, Zongo AW, Zeba MTA, Kiendrebeogo IT, Bado P, Kabré MK, Zohoncon TM, Djigma FW, Obiri-Yeboah D, Simpore J.
PMID: 34583364
Intervirology. 2021 Sep 28; doi: 10.1159/000519848. Epub 2021 Sep 28.

INTRODUCTION: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study...

Cite
Yelemkoure ET, Yonli AT, Sombie HK, et al. Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso. Intervirology. 2021;doi: 10.1159/000519848.
Yelemkoure, E. T., Yonli, A. T., Sombie, H. K., Tao, I., Zouré, A. A., Ouattara, A. K., Sorgho, A. P., Zongo, A. W., Zeba, M. T. A., Kiendrebeogo, I. T., Bado, P., Kabré, M. K., Zohoncon, T. M., Djigma, F. W., Obiri-Yeboah, D., & Simpore, J. (2021). Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso. Intervirology, . https://doi.org/10.1159/000519848
Yelemkoure, Edwige T, et al. "Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso." Intervirology vol. (2021). doi: https://doi.org/10.1159/000519848
Yelemkoure ET, Yonli AT, Sombie HK, Tao I, Zouré AA, Ouattara AK, Sorgho AP, Zongo AW, Zeba MTA, Kiendrebeogo IT, Bado P, Kabré MK, Zohoncon TM, Djigma FW, Obiri-Yeboah D, Simpore J. Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso. Intervirology. 2021 Sep 28; doi: 10.1159/000519848. Epub 2021 Sep 28. PMID: 34583364.
Copy Download .nbib Format: NLM
Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR.
PMID: 34971849
J Clin Virol. 2022 Jan;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21.

Over 90% of the COVID-19 patients manifest mild/moderate symptoms or are asymptomatic. Although comorbidities and dysregulation of immune response have been implicated in severe COVID-19, the host factors that associate with asymptomatic or mild infections have not been characterized....

Cite
Anantharaj A, Gujjar S, Verma N, et al. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2021;146:105060doi: 10.1016/j.jcv.2021.105060.
Anantharaj, A., Gujjar, S., Verma, N., Khan, N. A., Shaman, H., Sharanabasava, P., Das, A., Pandey, R., Pandey, A. K., & Medigeshi, G. R. (2022). Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 146105060. https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj, Anbalagan, et al. "Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses." Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology vol. 146 (2022): 105060. doi: https://doi.org/10.1016/j.jcv.2021.105060
Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol. 2022 Jan;146:105060. doi: 10.1016/j.jcv.2021.105060. Epub 2021 Dec 21. PMID: 34971849; PMCID: PMC8687718.
Copy Download .nbib Format: NLM
Clinical Trials of Oncolytic Viruses in Breast Cancer.

Frontiers in oncology

Carter ME, Koch A, Lauer UM, Hartkopf AD.
PMID: 35004328
Front Oncol. 2021 Dec 23;11:803050. doi: 10.3389/fonc.2021.803050. eCollection 2021.

Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties;...

Cite
Carter ME, Koch A, Lauer UM, et al. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol. 2021;11:803050doi: 10.3389/fonc.2021.803050.
Carter, M. E., Koch, A., Lauer, U. M., & Hartkopf, A. D. (2021). Clinical Trials of Oncolytic Viruses in Breast Cancer. Frontiers in oncology, 11803050. https://doi.org/10.3389/fonc.2021.803050
Carter, Mary E, et al. "Clinical Trials of Oncolytic Viruses in Breast Cancer." Frontiers in oncology vol. 11 (2021): 803050. doi: https://doi.org/10.3389/fonc.2021.803050
Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol. 2021 Dec 23;11:803050. doi: 10.3389/fonc.2021.803050. eCollection 2021. PMID: 35004328; PMCID: PMC8733599.
Copy Download .nbib Format: NLM
Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Pizzarelli G, Di Gregorio F, Romeo MA, Carboni F, Gallisai D, Solinas A, Malaguarnera M, Musumeci S.
PMID: 18031162
BioDrugs. 1999 Jul;12(1):55-63. doi: 10.2165/00063030-199912010-00006.

OBJECTIVE: Our study was designed to evaluate the effects of 2 dosage schedules of recombinant interferon (IFN)-alpha (IFNalpha-2a and IFNalpha-2b) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in beta-thalassaemic patients with chronic hepatitis C.DESIGN:...

Cite
Pizzarelli G, Di Gregorio F, Romeo MA, et al. Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. BioDrugs. 1999;12(1):55-63doi: 10.2165/00063030-199912010-00006.
Pizzarelli, G., Di Gregorio, F., Romeo, M. A., Carboni, F., Gallisai, D., Solinas, A., Malaguarnera, M., & Musumeci, S. (1999). Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 12(1), 55-63. https://doi.org/10.2165/00063030-199912010-00006
Pizzarelli, G, et al. "Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 12,1 (1999): 55-63. doi: https://doi.org/10.2165/00063030-199912010-00006
Pizzarelli G, Di Gregorio F, Romeo MA, Carboni F, Gallisai D, Solinas A, Malaguarnera M, Musumeci S. Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. BioDrugs. 1999 Jul;12(1):55-63. doi: 10.2165/00063030-199912010-00006. PMID: 18031162.
Copy Download .nbib Format: NLM
Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran.

Iranian journal of microbiology

Solgi G, Sabouri Ghannad M, Khalilian A, Majlesi A, Hajiloo M.
PMID: 26622972
Iran J Microbiol. 2015 Apr;7(2):109-17.

BACKGROUND AND OBJECTIVES: Hepatitis C Virus genotyping appears to be vital for predicting the response to antiviral therapy. The present study aimed to analyze the HCV genotypes in relation to persistence or clearance of the virus in residents of...

Cite
Solgi G, Sabouri Ghannad M, Khalilian A, et al. Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iran J Microbiol. 2015;7(2):109-17
Solgi, G., Sabouri Ghannad, M., Khalilian, A., Majlesi, A., & Hajiloo, M. (2015). Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iranian journal of microbiology, 7(2), 109-17.
Solgi, Ghasem, et al. "Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran." Iranian journal of microbiology vol. 7,2 (2015): 109-17.
Solgi G, Sabouri Ghannad M, Khalilian A, Majlesi A, Hajiloo M. Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iran J Microbiol. 2015 Apr;7(2):109-17. PMID: 26622972; PMCID: PMC4662778.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries